Hyperlipidemias

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

OtsukaJapan - Tokushima

1 program

HMG-CoA Reductase InhibitorPhase 41 trial

Active Trials

NCT01291641Completed342Est. Mar 2017

Hanmi PharmaceuticalKorea - Seoul

2 programs

HCP1105Phase 31 trial

HCP1105Phase 11 trial

Active Trials

NCT02941796Completed68Est. Oct 2016

NCT02551172Unknown270Est. Feb 2016

Golden BiotechnologyTaiwan - Taipei

1 program

AntroquinonolPhase 21 trial

Active Trials

NCT02719028Completed120Est. Mar 2019

Chong Kun Dang PharmaceuticalKorea - Seodaemun

2 programs

CKD-391 10/10mgPhase 11 trial

TPhase 12 trials

Active Trials

NCT04354987Completed44Est. Jan 2020

NCT07532148Not Yet Recruiting24Est. Aug 2027

NCT03793985Completed45Est. Nov 2018

Hyundai Pharmaceutical CoKorea - Seoul

1 program

HDDO-1756Phase 11 trial

Active Trials

NCT04755894Completed56Est. Jul 2020

BiocorpFrance - Issoire

1 program

SGB-3403Phase 11 trial

Active Trials

NCT06239714Unknown64Est. May 2025

MedpaceCINCINNATI, OH

1 program

SLN360Phase 11 trial

Active Trials

NCT04606602Completed70Est. Aug 2023

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsN/A1 trial

Active Trials

NCT00536965Completed951Est. Dec 2007

NCT00536796Completed1,096Est. Dec 2007

Colorado TherapeuticsCO - Louisville

1 program

Bean powderN/A1 trial

Active Trials

NCT01911390Completed41Est. Nov 2016

Oregon TherapeuticsFrance - Paris

1 program

Fruit and vegetable deliveriesN/A1 trial

Active Trials

NCT04036773Completed20Est. Dec 2020

Innovation PharmaceuticalsMA - Wakefield

1 program

Refined olive oilN/A1 trial

Active Trials

NCT03964857Unknown120Est. Jul 2024

T-TherapeuticsUK - Cambridge

1 program

TeleMOVE!N/A1 trial

Active Trials

NCT03330548CompletedEst. Mar 2021

Silence TherapeuticsGermany - Berlin

1 program

SLN360PHASE_1

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

OtsukaHMG-CoA Reductase Inhibitor

Hanmi PharmaceuticalHCP1105

Golden BiotechnologyAntroquinonol

Chong Kun Dang PharmaceuticalT

BiocorpSGB-3403

MedpaceSLN360

Hyundai Pharmaceutical CoHDDO-1756

Chong Kun Dang PharmaceuticalCKD-391 10/10mg

Chong Kun Dang PharmaceuticalT

Hanmi PharmaceuticalHCP1105

Oregon TherapeuticsFruit and vegetable deliveries

Innovation PharmaceuticalsRefined olive oil

T-TherapeuticsTeleMOVE!

Colorado TherapeuticsBean powder

AstraZenecaPercentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 3,331 patients across 16 trials

NCT01291641 OtsukaHMG-CoA Reductase Inhibitor

Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease

Start: Mar 2011Est. completion: Mar 2017342 patients

Phase 4Completed

NCT02551172 Hanmi PharmaceuticalHCP1105

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Start: Oct 2014Est. completion: Feb 2016270 patients

Phase 3Unknown

NCT02719028 Golden BiotechnologyAntroquinonol

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

Start: May 2016Est. completion: Mar 2019120 patients

Phase 2Completed

NCT07532148 Chong Kun Dang PharmaceuticalT

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start: Jun 2026Est. completion: Aug 202724 patients

Phase 1Not Yet Recruiting

NCT06239714 BiocorpSGB-3403

A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Start: Feb 2024Est. completion: May 202564 patients

Phase 1Unknown

NCT04606602 MedpaceSLN360

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Start: Nov 2020Est. completion: Aug 202370 patients

Phase 1Completed

NCT04755894 Hyundai Pharmaceutical CoHDDO-1756

HDDO-1756 Bio Equivalence Study

Start: Jun 2020Est. completion: Jul 202056 patients

Phase 1Completed

NCT04354987 Chong Kun Dang PharmaceuticalCKD-391 10/10mg

Compare the Pharmacokinetics and Safety of CKD-391

Start: Oct 2019Est. completion: Jan 202044 patients

Phase 1Completed

NCT03793985 Chong Kun Dang PharmaceuticalT

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

Start: Sep 2018Est. completion: Nov 201845 patients

Phase 1Completed

NCT02941796 Hanmi PharmaceuticalHCP1105

Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers

Start: Jun 2016Est. completion: Oct 201668 patients

Phase 1Completed

NCT04036773 Oregon TherapeuticsFruit and vegetable deliveries

Food Pharmacy at Oregon Health & Science University (OHSU) Knight Cardiovascular Institute (KCVI)

Start: Oct 2019Est. completion: Dec 202020 patients

N/ACompleted

NCT03964857 Innovation PharmaceuticalsRefined olive oil

Blended Oil Beneficial for Blood Lipids Management

Start: Nov 2018Est. completion: Jul 2024120 patients

N/AUnknown

NCT03330548 T-TherapeuticsTeleMOVE!

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

Start: Jul 2015Est. completion: Mar 2021

N/ACompleted

NCT01911390 Colorado TherapeuticsBean powder

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

Start: Jul 2013Est. completion: Nov 201641 patients

N/ACompleted

NCT00536796 AstraZenecaPercentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Start: Sep 2007Est. completion: Dec 20071,096 patients

N/ACompleted

NCT00536965 AstraZenecaPercentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Start: Jul 2007Est. completion: Dec 2007951 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.